Fundraising Fox
Tavo Biotherapeutics
Founded 2024 · 14 employees on LinkedIn · 2 known investors
Find your way into Tavo Biotherapeutics
Sign up to see every warm intro you have to Tavo Biotherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Tavo Biotherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Tavo Biotherapeutics develops novel treatments for glaucoma and retinal diseases, focusing on disease-modifying therapies that target the root biological mechanisms of vision loss. The company is advancing TAV-001, a topical therapy that modulates the autonomic nervous system to reduce intraocular pressure, improve blood flow to the optic nerve, and provide neuroprotection.
Investors · 2
How we know: Pureos Bioventures's portfolio page · Not right? Tell us
How we know: open dataset · investor-profiles · Not right? Tell us
Funding
SEC filings, press & company announcements$17M disclosed across 1 round · 2026
- $17MSeries AJun 2026 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $336K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $356.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $280K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Tavo Biotherapeutics do?
- Tavo Biotherapeutics develops novel treatments for glaucoma and retinal diseases, focusing on disease-modifying therapies that target the root biological mechanisms of vision loss. The company is advancing TAV-001, a topical therapy that modulates the autonomic nervous system to reduce intraocular pressure, improve blood flow to the optic nerve, and provide neuroprotection.
- Who are Tavo Biotherapeutics's investors?
- Tavo Biotherapeutics's investors include Pureos Bioventures, Polaris Partners.
- How much funding has Tavo Biotherapeutics raised?
- Tavo Biotherapeutics has disclosed $17M raised across 1 round.